+

CL2008002867A1 - Uso de (s,s)-reboxetina en la preparacion de un medicamento util en el tratamiento de un trastorno de ajuste o adaptacion, anorexia nerviosa, bulimia nerviosa, trastorno sistemico, trastorno de intoxicacion, trastorno compulsivos obsesivos, trastorno de desarrollo especifico, trastorno tic, entre otras (sol. div. 1765-00). - Google Patents

Uso de (s,s)-reboxetina en la preparacion de un medicamento util en el tratamiento de un trastorno de ajuste o adaptacion, anorexia nerviosa, bulimia nerviosa, trastorno sistemico, trastorno de intoxicacion, trastorno compulsivos obsesivos, trastorno de desarrollo especifico, trastorno tic, entre otras (sol. div. 1765-00).

Info

Publication number
CL2008002867A1
CL2008002867A1 CL2008002867A CL2008002867A CL2008002867A1 CL 2008002867 A1 CL2008002867 A1 CL 2008002867A1 CL 2008002867 A CL2008002867 A CL 2008002867A CL 2008002867 A CL2008002867 A CL 2008002867A CL 2008002867 A1 CL2008002867 A1 CL 2008002867A1
Authority
CL
Chile
Prior art keywords
disorder
adjustment
nervosa
reboxetine
div
Prior art date
Application number
CL2008002867A
Other languages
English (en)
Inventor
Clyde Marshall Robert
Ahmed Saeeduddlin
Mcarthur Robert
P Taylor Duncan
Birgerson Lars
H F Wong Erik
C Pasquale
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002867(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of CL2008002867A1 publication Critical patent/CL2008002867A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de (s,s)-reboxetina en la preparación de un medicamento útil en el tratamiento de un trastorno de ajuste o adaptación, anorexia nerviosa, bulimia nerviosa, trastorno sistémico, trastorno de intoxicación, trastorno compulsivos obsesivos, trastorno de desarrollo específico, trastorno tic, entre otras (Sol. Div. 1765-00).
CL2008002867A 1999-07-01 2008-09-26 Uso de (s,s)-reboxetina en la preparacion de un medicamento util en el tratamiento de un trastorno de ajuste o adaptacion, anorexia nerviosa, bulimia nerviosa, trastorno sistemico, trastorno de intoxicacion, trastorno compulsivos obsesivos, trastorno de desarrollo especifico, trastorno tic, entre otras (sol. div. 1765-00). CL2008002867A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14196899P 1999-07-01 1999-07-01
US14413199P 1999-07-16 1999-07-16
US15825699P 1999-10-06 1999-10-06
US17038199P 1999-12-13 1999-12-13

Publications (1)

Publication Number Publication Date
CL2008002867A1 true CL2008002867A1 (es) 2009-01-09

Family

ID=27495506

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2008002866A CL2008002866A1 (es) 1999-07-01 2008-09-26 Uso de (s,s)-reboxetina en la preparacion de un medicamento util en el tratamiento de un trastorno adictivo, trastorno mental, trastorno de deficit atencional, trastorno bipolar, obesidad, trastorno de panico, trastorno psicotico, sindrome de inhibicion selectiva de la recaptacion de serotonina, entre otras (sol. div. 1765-00).
CL2008002868A CL2008002868A1 (es) 1999-07-01 2008-09-26 Uso de reboxetina racemica o una sal de la misma para el tratamiento o prevencion de la fibromialgia u otro desorden somatoforme, neuropatia periferica, migraña, dolor de cabeza y sindrome de fatiga cronica.
CL2008002867A CL2008002867A1 (es) 1999-07-01 2008-09-26 Uso de (s,s)-reboxetina en la preparacion de un medicamento util en el tratamiento de un trastorno de ajuste o adaptacion, anorexia nerviosa, bulimia nerviosa, trastorno sistemico, trastorno de intoxicacion, trastorno compulsivos obsesivos, trastorno de desarrollo especifico, trastorno tic, entre otras (sol. div. 1765-00).

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2008002866A CL2008002866A1 (es) 1999-07-01 2008-09-26 Uso de (s,s)-reboxetina en la preparacion de un medicamento util en el tratamiento de un trastorno adictivo, trastorno mental, trastorno de deficit atencional, trastorno bipolar, obesidad, trastorno de panico, trastorno psicotico, sindrome de inhibicion selectiva de la recaptacion de serotonina, entre otras (sol. div. 1765-00).
CL2008002868A CL2008002868A1 (es) 1999-07-01 2008-09-26 Uso de reboxetina racemica o una sal de la misma para el tratamiento o prevencion de la fibromialgia u otro desorden somatoforme, neuropatia periferica, migraña, dolor de cabeza y sindrome de fatiga cronica.

Country Status (31)

Country Link
US (18) US6465458B1 (es)
EP (3) EP1196172B1 (es)
JP (3) JP2003503450A (es)
KR (5) KR100717660B1 (es)
CN (5) CN1660110A (es)
AR (1) AR035158A1 (es)
AT (9) ATE305306T1 (es)
AU (2) AU771258B2 (es)
BR (1) BR0012136A (es)
CA (2) CA2643231A1 (es)
CL (3) CL2008002866A1 (es)
CO (1) CO5190662A1 (es)
CZ (1) CZ299847B6 (es)
DE (9) DE60023043T2 (es)
DK (4) DK1632234T3 (es)
EA (6) EA011094B1 (es)
ES (9) ES2246485T3 (es)
GE (1) GEP20094798B (es)
HK (2) HK1049630A1 (es)
HU (1) HUP0201623A3 (es)
IL (3) IL147246A0 (es)
MX (1) MXPA02000562A (es)
MY (1) MY137348A (es)
NO (4) NO20016406L (es)
NZ (2) NZ533243A (es)
PE (1) PE20010684A1 (es)
PL (1) PL196996B1 (es)
PT (5) PT1632234E (es)
SK (5) SK286864B6 (es)
TW (9) TWI294779B (es)
WO (1) WO2001001973A2 (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ533243A (en) 1999-07-01 2005-12-23 Upjohn Co Optically pure (S.S) reboxetine in the treatment of conditions such as those involving cognitive function in which inhibiting reuptake of norepinephrine (nor adrenaline) provides relief
AR026610A1 (es) * 1999-12-01 2003-02-19 Ucb Sa Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
NZ531172A (en) 2000-04-21 2005-07-29 Upjohn Co Heterocyclic amine-type compounds for treating fibromyalgia and chronic fatigue syndrome
NZ522115A (en) * 2000-04-21 2004-07-30 Upjohn Co Selected compounds for the treatment of fibromyalgia and chronic fatigue syndrome
WO2002036125A1 (en) * 2000-10-31 2002-05-10 Head Explorer A/S The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
BR0115301A (pt) * 2000-11-15 2004-12-14 Lilly Co Eli Uso de um inibidor seletivo da recaptação de norepinefrina
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
EP1627639B1 (en) * 2001-06-19 2009-12-23 Norbert Müller Use of COX-2 inhibitors for the treatment of affective disorders
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
ATE365035T1 (de) * 2001-11-30 2007-07-15 Lilly Co Eli Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
CA2467802A1 (en) * 2001-12-11 2003-06-19 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
AU2003213009A1 (en) * 2002-02-12 2003-09-04 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US20030232805A1 (en) * 2002-04-24 2003-12-18 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
EP3173082A1 (en) 2002-05-17 2017-05-31 Duke University Method for treating obesity
AU2003227520B9 (en) * 2002-05-30 2008-06-26 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
WO2003106441A1 (en) * 2002-06-17 2003-12-24 Pharmacia Italia S.P.A. Pharmaceutical salts of reboxetine
AR040680A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
BR0313411A (pt) * 2002-08-14 2005-06-28 Pharmacia & Upjohn Co Llc Uso de reboxetina para o tratamento de ondas de calor
AU2003261245A1 (en) * 2002-08-23 2004-03-11 Eli Lilly And Company Benzyl morpholine derivatives
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
ES2315525T3 (es) 2002-08-23 2009-04-01 Eli Lilly And Company Derivados de 2-(feniltiometil)-morfolina para uso como inhibidores selectivos de la recaptacion de norepinefrina.
EP1558231A4 (en) * 2002-10-03 2010-09-08 Cypress Bioscience Inc DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
EP2286817A3 (en) * 2003-01-13 2011-06-15 Edusa Pharmaceuticals, Inc Method of treating functional bowel disorders
DE602004005814T2 (de) * 2003-01-13 2008-01-10 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
CA2519379A1 (en) * 2003-04-04 2004-10-21 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
EP1617832B1 (en) 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0319793D0 (en) * 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
EP1660065A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
CA2537402C (en) * 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
ES2307071T3 (es) * 2003-12-12 2008-11-16 Eli Lilly And Company Inhibidores selectivos de la recaptacion de norepinefrina para el tratamiento de sofocos.
US7595315B2 (en) 2003-12-23 2009-09-29 Eli Lilly And Company Morpholine derivatives as norepinephrine reuptake inhibitors
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
GEP20084550B (en) * 2004-04-30 2008-11-25 Warner Lambert Co Substituted morpholine compounds for the treatment of central nervous system disorders
KR100871272B1 (ko) * 2004-04-30 2008-11-28 화이자 인코포레이티드 모폴린 화합물
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
MXPA06014389A (es) * 2004-06-09 2007-02-19 Pfizer Uso de la reboxetina para el tratamiento del dolor.
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
SI1789021T1 (sl) 2004-08-13 2012-02-29 Boehringer Ingelheim Int Tabletna formulacija s podaljšanim sproščanjem, ki vsebuje pramipeksol ali njegovo farmacevtsko sprejemljivo sol
AU2005290980A1 (en) * 2004-10-01 2006-04-13 Neurocure Ltd Use of pharmaceutical compositions of lofepramine for the treatment of ADHD, CFS, FM and depression
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
EP2292220A3 (en) 2005-11-22 2012-01-04 Orexigen Therapeutics, Inc. Composition and methods for increasing insulin sensitivity
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
ES2383768T3 (es) * 2006-06-28 2012-06-26 Chelsea Therapeutics Inc. Composiciones farmacéuticas que comprenden droxidopa
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
CA2680272A1 (en) 2007-03-09 2008-09-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
MX2009011858A (es) * 2007-04-30 2010-01-14 Adolor Corp Composiciones de (-)-e-10-oh-nt y metodos para su sintesis y uso.
JP2010526820A (ja) * 2007-05-07 2010-08-05 チェルシー・セラピューティクス，インコーポレイテッド 気分障害、睡眠障害、または注意欠陥障害を治療するドロキシドパおよびその医薬組成物
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US8475823B2 (en) 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2434250T3 (es) 2008-07-24 2013-12-16 Theravance, Inc. Compuestos de 3-(fenoxifenilmetil)pirrolidina
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2010044016A1 (en) * 2008-10-17 2010-04-22 Pfizer Limited Novel uses for esreboxetine and racemic reboxetine
JP2012524098A (ja) * 2009-04-15 2012-10-11 セラヴァンス， インコーポレーテッド ３−（フェノキシピロリジン−３−イル−メチル）ヘテロアリール、３−（フェニルピロリジン−３−イルメトキシ）ヘテロアリールおよび３−（ヘテロアリールピロリジン−３−イルメトキシ）ヘテロアリール化合物
CN102471258A (zh) * 2009-07-13 2012-05-23 施万制药 3-苯氧基甲基吡咯烷化合物
WO2011011231A1 (en) 2009-07-21 2011-01-27 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
ES2533434T3 (es) 2010-10-11 2015-04-10 Theravance Biopharma R&D Ip, Llc Inhibidores de la captación de la serotonina
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
KR20220042241A (ko) 2012-06-06 2022-04-04 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
WO2016077724A1 (en) 2014-11-13 2016-05-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education (2-amino-4(arylamino)phenyl) carbamates
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
EP3693020A1 (en) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Potassium enriched topical formulations for pain relief and sleep aid
BR112022010677A2 (pt) * 2019-12-03 2022-08-16 Axsome Therapeutics Inc Uso de reboxetina para tratar transtornos do sistema nervoso

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) * 1980-03-19 1984-08-14 Matsushita Electric Industrial Co., Ltd. Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en) 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ZA921292B (en) 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
US5281624A (en) 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL111786A0 (en) 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
WO1997035584A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
CZ296263B6 (cs) 1996-03-25 2006-02-15 Eli Lilly And Company Farmaceutická kompozice pro lécení bolesti a jejípouzití
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US20020015713A1 (en) 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
WO2000000120A1 (en) 1998-06-29 2000-01-06 Pharmaceuticals Applications Asociates, Llc Methods and transdermal compositions for pain relief
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6572880B2 (en) 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
ATE172117T1 (de) 1996-11-27 1998-10-15 Pfleger R Chem Fab Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
JP2002503224A (ja) 1997-04-11 2002-01-29 エリ リリー アンド カンパニー 疼痛を処置するための組成物
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
AU5155198A (en) 1997-08-28 1999-03-22 Robert Murdock Method and composition for transdermal administration of pharmacologic agent
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
AU9214498A (en) 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
CA2306233A1 (en) 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
JP2002511414A (ja) * 1998-04-09 2002-04-16 ファルマシア・アンド・アップジョン・カンパニー 神経疾患のための新しい治療
IT1305322B1 (it) 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
BR9909559A (pt) * 1998-05-08 2000-12-19 Upjohn Co Novas combinações de drogas
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
NZ533243A (en) * 1999-07-01 2005-12-23 Upjohn Co Optically pure (S.S) reboxetine in the treatment of conditions such as those involving cognitive function in which inhibiting reuptake of norepinephrine (nor adrenaline) provides relief
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
JP2003523382A (ja) * 2000-02-24 2003-08-05 ファルマシア・アンド・アップジョン・カンパニー 新規な薬物の組合せ
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Also Published As

Publication number Publication date
DE60022917T2 (de) 2006-06-29
DK1459749T3 (da) 2006-01-09
US6610690B2 (en) 2003-08-26
EA008381B1 (ru) 2007-04-27
ATE305306T1 (de) 2005-10-15
DE60023043T2 (de) 2006-06-14
WO2001001973A2 (en) 2001-01-11
CA2375908A1 (en) 2001-01-11
DE60026627T2 (de) 2007-02-01
DE60022916D1 (de) 2006-02-09
KR100935277B1 (ko) 2010-01-06
DE60019473T2 (de) 2006-02-23
DE60035232T2 (de) 2008-02-14
CL2008002868A1 (es) 2009-01-09
US20030040464A1 (en) 2003-02-27
EP2090312A1 (en) 2009-08-19
DE60020613D1 (de) 2005-07-07
PT1459751E (pt) 2005-11-30
TW200607509A (en) 2006-03-01
EP1196172A2 (en) 2002-04-17
KR20060099544A (ko) 2006-09-19
SK286669B6 (sk) 2009-03-05
TW200607510A (en) 2006-03-01
US7317011B2 (en) 2008-01-08
SK286668B6 (sk) 2009-03-05
IL187512A0 (en) 2008-06-05
US20090247528A1 (en) 2009-10-01
HUP0201623A2 (en) 2002-09-28
WO2001001973A3 (en) 2002-01-17
EA005029B1 (ru) 2004-10-28
ES2285645T3 (es) 2007-11-16
TWI298255B (en) 2008-07-01
ES2239311T3 (es) 2005-09-16
NZ515885A (en) 2004-08-27
EP1196172B1 (en) 2006-03-15
DE60023043D1 (de) 2006-02-16
EA006652B1 (ru) 2006-02-24
US7338953B2 (en) 2008-03-04
CN1660109A (zh) 2005-08-31
PE20010684A1 (es) 2001-06-24
NZ533243A (en) 2005-12-23
CN1660111A (zh) 2005-08-31
GEP20094798B (en) 2009-10-26
ATE319453T1 (de) 2006-03-15
TW200607511A (en) 2006-03-01
PT1632234E (pt) 2007-07-09
DE60026704T2 (de) 2006-10-19
KR100948757B1 (ko) 2010-03-23
ATE320257T1 (de) 2006-04-15
TWI245631B (en) 2005-12-21
AU2004202096A1 (en) 2004-06-10
ATE304358T1 (de) 2005-09-15
CN1660108A (zh) 2005-08-31
HK1049630A1 (en) 2003-05-23
US20020128173A1 (en) 2002-09-12
ES2242175T3 (es) 2005-11-01
CN1660110A (zh) 2005-08-31
US20060128705A1 (en) 2006-06-15
PT1459750E (pt) 2005-08-31
ES2246485T3 (es) 2006-02-16
US6465458B1 (en) 2002-10-15
HK1076723A1 (en) 2006-01-27
MY137348A (en) 2009-01-30
EA200801805A1 (ru) 2008-12-30
IL187513A0 (en) 2008-06-05
IL147246A0 (en) 2002-08-14
US7723334B2 (en) 2010-05-25
DE60035232D1 (de) 2007-07-26
DK1459750T3 (da) 2005-08-15
US6703389B2 (en) 2004-03-09
EP2087892A2 (en) 2009-08-12
US7276503B2 (en) 2007-10-02
US20080096890A1 (en) 2008-04-24
CN1379672A (zh) 2002-11-13
AR035158A1 (es) 2004-05-05
CZ20014625A3 (cs) 2002-08-14
DE60020613T2 (de) 2006-03-16
TW200607512A (en) 2006-03-01
ATE296634T1 (de) 2005-06-15
CA2375908C (en) 2006-05-30
EA200400589A1 (ru) 2004-12-30
EA200801806A1 (ru) 2008-12-30
ATE292971T1 (de) 2005-04-15
DE60022692T2 (de) 2006-06-22
TWI294779B (en) 2008-03-21
AU5633700A (en) 2001-01-22
KR20050053799A (ko) 2005-06-08
CO5190662A1 (es) 2002-08-29
US20060135521A1 (en) 2006-06-22
NO20016406D0 (no) 2001-12-28
TW200407146A (en) 2004-05-16
ES2258251T3 (es) 2006-08-16
US6642235B2 (en) 2003-11-04
BR0012136A (pt) 2002-06-11
CA2643231A1 (en) 2001-01-11
CL2008002866A1 (es) 2009-01-09
DE60022916T2 (de) 2006-07-06
DE60026627D1 (de) 2006-05-04
DK1196172T3 (da) 2006-06-19
DE60022917D1 (de) 2006-02-09
ATE305307T1 (de) 2005-10-15
NO20091159L (no) 2002-02-19
PL196996B1 (pl) 2008-02-29
PT1459748E (pt) 2005-08-31
TW200922594A (en) 2009-06-01
DE60019473D1 (de) 2005-05-19
ES2246488T3 (es) 2006-02-16
KR100717660B1 (ko) 2007-05-15
US20040147614A1 (en) 2004-07-29
JP2006143749A (ja) 2006-06-08
US20060264436A1 (en) 2006-11-23
CN1205935C (zh) 2005-06-15
US20080103147A1 (en) 2008-05-01
JP2006321815A (ja) 2006-11-30
EP2087892A3 (en) 2009-09-30
US20080103146A1 (en) 2008-05-01
US20060142289A1 (en) 2006-06-29
ATE364386T1 (de) 2007-07-15
PT1196172E (pt) 2006-05-31
KR20090087134A (ko) 2009-08-14
EA011094B1 (ru) 2008-12-30
KR20090087135A (ko) 2009-08-14
EA200200111A1 (ru) 2002-06-27
ATE305788T1 (de) 2005-10-15
NO20016406L (no) 2002-02-19
TWI298254B (en) 2008-07-01
EA200501496A1 (ru) 2006-06-30
TW200920378A (en) 2009-05-16
US20080103145A1 (en) 2008-05-01
ES2247572T3 (es) 2006-03-01
DK1632234T3 (da) 2007-09-17
NO20091158L (no) 2002-02-19
US7241762B2 (en) 2007-07-10
HUP0201623A3 (en) 2004-12-28
EA200700232A1 (ru) 2007-06-29
DE60022692D1 (de) 2005-10-20
KR100704319B1 (ko) 2007-04-09
US20060135520A1 (en) 2006-06-22
SK286864B6 (sk) 2009-06-05
MXPA02000562A (es) 2002-07-02
AU2004202096B2 (en) 2005-10-20
CN1289090C (zh) 2006-12-13
US20020086864A1 (en) 2002-07-04
US20040058925A1 (en) 2004-03-25
SK19382001A3 (sk) 2002-07-02
ES2258010T3 (es) 2006-08-16
TW200914027A (en) 2009-04-01
DE60026704D1 (de) 2006-05-11
WO2001001973A8 (en) 2001-05-17
US20020107249A1 (en) 2002-08-08
US6987107B2 (en) 2006-01-17
US20020061910A1 (en) 2002-05-23
AU771258B2 (en) 2004-03-18
SK286104B6 (sk) 2008-03-05
JP2003503450A (ja) 2003-01-28
KR20020015363A (ko) 2002-02-27
NO20091168L (no) 2002-02-19
SK286667B6 (sk) 2009-03-05
ES2246487T3 (es) 2006-02-16
PL352252A1 (en) 2003-08-11
TWI293250B (en) 2008-02-11
CZ299847B6 (cs) 2008-12-10

Similar Documents

Publication Publication Date Title
CL2008002867A1 (es) Uso de (s,s)-reboxetina en la preparacion de un medicamento util en el tratamiento de un trastorno de ajuste o adaptacion, anorexia nerviosa, bulimia nerviosa, trastorno sistemico, trastorno de intoxicacion, trastorno compulsivos obsesivos, trastorno de desarrollo especifico, trastorno tic, entre otras (sol. div. 1765-00).
ATE320457T1 (de) Polyurethanlösungen mit alkoxysilanstruktureinheiten
BR9916896A (pt) Diaril aminas substituìdas com 1-heterociclo
GT199900158A (es) "combinaciones para la diabetes"
IL231675A (en) Concentrated protein compositions with reduced viscosity
NO20020140L (no) Mikromaskinert speilanordning
TR199902516T2 (xx) Kalsilitik bile�imleri.
ID29076A (id) Kombinasi senyawa aktif fungisida
BR9903989A (pt) Dispositivo elevador
EP2172771A3 (en) High Speed, high resolution method for capillary electrophoresis
GB0005700D0 (en) Therapy
DE60005031D1 (de) Partikel mit kontrollierter freisetzungsrate
PT1276374E (pt) Peca porosa anti-microbiana tendo por base um material polimerico enxertado com grupos benzalconio
BR0208483A (pt) Estrutura de suporte para ferramenta compreendendo aparelho umedecedor
EP0990635A4 (en) HYDROXYCYCLOPENTANONE
SE0300566D0 (sv) Mellanvägg för bipolär batterielektrod
AR008860A1 (es) Empleo de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica
DE69124730D1 (de) Poröses, gasstatisches Lager
IT1294790B1 (it) Dispositivo elettrocromico per l'attenuazione o il filtraggio della luce
BR9814519A (pt) Uso de compostos quìmicos promotores de oxidação na oxidação de polìmero contendo configuração álcool tipo galactose oxidável
IL148234A0 (en) Composition for ivf
AU6290398A (en) Inclusion complexes in aqueous solution
BR9609310A (pt) Derivados de 1,3-OXA(TIA)ZINA
DE50003506D1 (de) Glaspulver und dessen Verwendung
UA67058A (en) Composition for treating periodontitis
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载